Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Amniotic Membrane in Total Knee Replacements to Reduce Scarring

This study has been completed.
Information provided by (Responsible Party):
MiMedx Group, Inc. Identifier:
First received: November 21, 2013
Last updated: September 21, 2015
Last verified: September 2015
The overall objective of this study is to evaluate the effectiveness of dHACM in reducing scar tissue formation in total knee replacement patients.

Condition Intervention
Procedure: Total Knee Arthroplasty
Other: Application of dHACM

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Participant)
Primary Purpose: Treatment
Official Title: A Prospective Randomized Clinical Trial Using Dehydrated Human Amnion/Chorion Membrane (dHACM) in Total Knee Replacement Patients to Reduce Post-operative Scarring.

Resource links provided by NLM:

Further study details as provided by MiMedx Group, Inc.:

Primary Outcome Measures:
  • Increased range of motion between both groups as measured by goniometer [ Time Frame: 6 weeks ]

Secondary Outcome Measures:
  • Incidence of need for manual manipulation of affected knee [ Time Frame: 6 weeks ]

Other Outcome Measures:
  • Increased Quality of Life as assessed by WOMAC and SF-36 [ Time Frame: 6 weeks ]
    Western Ontario and McMaster Universities Arthritis Index (WOMAC) and Short Form 36 (SF-36) are measures of patient health status and quality of life.

Enrollment: 52
Study Start Date: January 2014
Study Completion Date: October 2014
Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: dHACM
Total knee arthroplasty, per the usual practice of the physician with application of dHACM between the underlying fascia and the overlying skin layers to reduce scar formation
Procedure: Total Knee Arthroplasty
Total knee arthroplasty, per the usual practice of the physician.
Other: Application of dHACM
Application of dHACM at end of procedure before closing wound between the underlying fascia and the overlying skin layers to reduce scar formation
Total knee arthroplasty, per the usual practice of the physician without application of dHACM.
Procedure: Total Knee Arthroplasty
Total knee arthroplasty, per the usual practice of the physician.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Are adults ages 18 or older.
  2. Are diagnosed with advanced osteoarthritis as determined by clinical exam and necessitate total knee replacement.
  3. Have a willingness to comply with follow-up examination.
  4. Have ability to give full written consent.

Exclusion Criteria:

  1. Has had a previous total or partial joint replacement performed at the same site
  2. Has a planned bilateral procedure at this time. Bilateral patients can be enrolled if the procedures are staged.
  3. Has signs or symptoms of any other disease which could result in allograft failure, or has experienced allograft failure in the past.
  4. Has used any investigational drug(s) or therapeutic device(s) within 30 days preceding screening.
  5. Is pregnant or may become pregnant during the study.
  6. Is a prisoner.
  7. Has any condition(s) which seriously compromises the subject's ability to participate in this study, or has a known history of poor adherence with medical treatment.
  8. Is currently taking medications which could affect allograft incorporation (supervising physician's discretion).
  9. Is confined to bed or a wheelchair.
  10. Has clinical signs and symptoms of local infection at the site.
  11. Has autoimmune disease or a known history of having Acquired Immunodeficiency Syndrome (AIDS) or HIV.
  12. Has current diagnosis of cancer at the site.
  13. Has had prior radiation therapy treatment at the site.
  14. Is currently taking anticoagulant therapy.
  15. Is unable to sign or understand informed consent.
  16. Has a history of drug or alcohol abuse within last 12 months.
  17. Is allergic to Aminoglycoside antibiotics (such as gentamicin and/or streptomycin).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02088567

United States, Georgia
Georgia Knee and Sports Medicine
Decatur, Georgia, United States, 30033
Sponsors and Collaborators
MiMedx Group, Inc.
Principal Investigator: Maurice Jove, MD Georgia Knee and Sports Medicine
  More Information

Responsible Party: MiMedx Group, Inc. Identifier: NCT02088567     History of Changes
Other Study ID Numbers: AFTKR001
Study First Received: November 21, 2013
Last Updated: September 21, 2015

Additional relevant MeSH terms:
Pathologic Processes processed this record on April 27, 2017